pyridinolcarbamate has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shor, NA | 1 |
| Helunenko, AM | 1 |
| Petrunia, AM | 1 |
| Zelenyĭ, II | 1 |
1 other study available for pyridinolcarbamate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[Disorders of the blood microcirculation in patients with suppurative-necrotic complications in diabetes mellitus and the approaches to their correction].
Topics: Adult; Aged; Chronic Disease; Combined Modality Therapy; Conjunctiva; Diabetes Mellitus, Type 1; Dia | 1998 |